Wellington Global Homepage
Change
Showing
of
Insights Posts
Advocating for better climate disclosures to improve investment outcomes
Members of our Sustainable Investment Team share recent advocacy efforts with policymakers and standard setters around the world.
Continue reading
Quick Take
2023-10-31
The critical role of ESG in private equity
Explore our full ESG insights for private companies series with our latest research on governance, DEI, climate, and much more.
Continue reading
Article
2024-10-31
New IFRS financial reporting standards: three key investment implications for insurers
ALM and Regulatory Capital Strategist Francisco Sebastian examines the investment impact of the new IFRS reporting standards and considers three potential investment implications.
Continue reading
Quick Take
2023-07-31
New IFRS financial reporting standards: how should insurers implement the changes?
ALM and Regulatory Capital Strategist Francisco Sebastian assesses how insurance companies should implement upcoming changes to International Financial Reporting Standards to create value for their shareholders and mutual members.
Continue reading
Quick Take
2023-07-31
New IFRS reporting standards: a game changer for insurers?
From 1 January 2023, new requirements set out in the International Financial Reporting Standards (IFRS) on Insurance Contracts and Financial Instruments will change how insurance companies are required to measure and report their performance
Continue reading
Quick Take
2023-06-30
Crypto beyond the hype: Insights for institutional investors
We highlight a few practical insights on cryptocurrencies for institutional investors evaluating the asset class, including our views on custody, regulation, and more.
Continue reading
Quick Take
2022-12-31
A US insurer’s roadmap for navigating the new RBC regs
With the NAIC’s latest revisions to risk-based capital (RBC) charges now on the books, what should US insurers be focused on moving forward? And how have the relative value propositions across fixed income assets and other investments changed as a result? Multi-Asset Insurance Strategist Tim Antonelli and Investment Specialist Geoff Austein-Miller share their views and insights.
Continue reading
Whitepaper
2023-03-31
Why I’m getting more bullish on biotech
The biotechnology sector, especially SMID-cap biotech equities, suffered a dramatic drawdown in 2021. Investor sentiment toward the sector remains poor, but my outlook has become increasingly bullish as multiple headwinds facing biotech over the past year or so begin to abate and turn into potential tailwinds for 2022 and beyond. Encouragingly, the level of innovation across the industry has never been higher, in my view. I believe many biotech stocks may be nearing a bottom, even though the exact timing of (and catalyst for) a rebound remains unclear as of this writing.
Continue reading
Quick Take
2022-06-30
Rising short-termism in fintech has a silver lining
Global Industry Analyst Matt Ross looks at the fintech sector as an example of the long-term alpha opportunity that may be available to patient equity investors.
Continue reading
Article
2022-03-14
Chinese regulation: Lessons from after-school tutoring
Investment Director Graham Proud distills our China and EM equity specialists’ views on China’s latest regulatory move — including why investors shouldn’t jump to conclusions regarding potential implications for Chinese internet companies.
Continue reading
Article
2021-10-31
URL References
Related Insights